19 completed, 5 terminated, 3 withdrawn, 2 active not recruiting. 18 Phase 3, 6 Phase 4, 5 Phase 2, 3 Phase 1, 2 Early Phase 1.
Follow IV Placebo: new trials by email Literature Review of IV Placebo trials Research Report on IV Placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Pain Improvement for Intravenous Versus Oral Acetaminophen in Acute Pelvic Pain Acetaminophen 1000mg PO, IV Acetaminophen 1000mg, IV Placebo - Pelvic Pain | Phase 4 | Not yet recruiting | Montefiore Medical Center | 140 | 2026-11-01 | 2026-09-23 |
| A Study of Fosmanogepix in Healthy Adult Chinese Subjects Oral Fosmanogepix, IV Fosmanogepix, IV placebo - Healthy | Phase 1 | Completed | Basilea Pharmaceutica | 54 | 2025-04-14 | 2026-04-06 |
| A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) IV Tulisokibart, SC Tulisokibart, IV Placebo - Crohn's Disease | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1200 | 2024-06-05 | 2026-10-23 |
| Severe Erythema Multiforme - CORTICO Prednisone 20 Mg, Oral Placebo, Methylprednisolone 120 Mg - Erythema Multiforme | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 96 | 2024-05-01 | 2024-02-20 |
| NAC vs Placebo on Opioid Use for Hysterectomy IV N-acetylcysteine, IV Placebo - Hysterectomy | Phase 3 | Completed | Medical University of South Carolina | 240 | 2023-11-30 | 2026-10-09 |
| A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) IV Tulisokibart, IV Placebo, SC Tulisokibart - Ulcerative Colitis | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 1109 | 2023-10-25 | 2026-09-28 |
| Safety and Efficacy Study of IV Ganaxolone as Adjuvant Therapy for Established Status Epilepticus (ESE) IV Ganaxolone, IV Placebo - Status Epilepticus | Phase 2 | Withdrawn | Marinus Pharmaceuticals | 2023-04-01 | 2024-05-07 | |
| Theophylline for Depression Study Theophylline ER, PO placebo, Lipopolysaccharide (LPS) - Depression | Early Phase 1 | Withdrawn | University of California, Los Angeles | 2023-03-01 | 2021-11-05 | |
| Myasthenia Gravis Inebilizumab Trial inebilizumab, IV Placebo - Myasthenia Gravis | Phase 3 | Active not recruiting | Amgen | 238 | 2020-10-15 | 2026-05-15 |
| Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012) Lenvatinib, Pembrolizumab, Oral Placebo - Carcinoma, Hepatocellular | Phase 3 | Terminated | Merck Sharp & Dohme LLC | 480 | 2020-05-22 | 2026-09-03 |
| Intravenous Ketamine for Pain Control During First Trimester Surgical Abortion PO Morphine, IV Fentanyl, IV Ketamine - Abortion in First Trimester | Phase 3 | Suspended | Dr. Marie Eve Sophie Bussiere-Cote | 123 | 2019-06-10 | 2022-09-08 |
| IV Acetaminophen as Adjuvant Analgesic to Hydromorphone - Emergency Department Patients IV acetaminophen, IV placebo, hydromorphone - Acute Pain | Phase 3 | Completed | Albert Einstein College of Medicine | 162 | 2018-11-27 | 2022-03-02 |
| Leucine for Depression Study (L-DEP) leucine, PO placebo, lipopolysaccharide (LPS) - Depression | Early Phase 1 | Terminated | University of California, Los Angeles | 59 | 2018-09-01 | 2023-06-08 |
| Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) Ublituximab, Teriflunomide, Oral Placebo - Relapsing Multiple Sclerosis (RMS) | Phase 3 | Completed | TG Therapeutics, Inc. | 549 | 2017-09-19 | 2021-12-06 |
| Inhaled vs IV Opioid Dosing for the Initial Treatment of Severe Acute Pain in the Emergency Department inhaled titration of morphine chlorhydrate, IV placebo, Inhaled placebo - Pain, Acute, Emergencies | Phase 3 | Completed | University Hospital, Rouen | 226 | 2017-09-19 | 2026-02-06 |
| Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) Ublituximab, Teriflunomide, Oral Placebo - Relapsing Multiple Sclerosis (RMS) | Phase 3 | Completed | TG Therapeutics, Inc. | 545 | 2017-08-25 | 2021-12-06 |
| Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH IV acetaminophen, Oral acetaminophen, Oral placebo - Subarachnoid Hemorrhage, Stroke | Phase 4 | Terminated | Milton S. Hershey Medical Center | 3 | 2017-01-05 | 2019-04-10 |
| Superficial Cervical Nerve Block vs NSAIDs for the Relief of Shoulder Pain After Laparoscopic Surgeries Superficial cervical nerve block, NSAID, General anesthesia - Relieve Shoulder Pain After Laparoscopic Surgeries | Not applicable | Completed | Makassed General Hospital | 60 | 2016-06-01 | 2017-11-06 |
| Reduction in Pain Intensity Following IV or Oral Pain-relieving Products IV Acetaminophen (Treatment A), Oral Acetaminophen (Treatment B), Placebo (Treatment C) - Pain | Phase 4 | Completed | Mallinckrodt | 79 | 2015-12-07 | 2020-02-05 |
| HepciFer Study: Hepcidin Overexpression After Hepatectomy : Does Iron Supplementation Make Sense ? IV iron, IV placebo - Anemia, Postoperative Blood Loss | Phase 3 | Completed | University Hospital, Geneva | 50 | 2015-10-01 | 2017-05-05 |
Showing 20 of 34. Sign in to see all of them.
Pain (4) · Acute Pain (2) · Depression (2) · Emergencies (2) · Multiple Sclerosis, Relapsing-Remitting (2) · Pain, Postoperative (2) · Anemia (1) · Asthma (1) · Carcinoma, Hepatocellular (1) · Colitis, Ulcerative (1) · Crohn Disease (1) · Dystocia (1) · Erythema (1) · Erythema Multiforme (1) · Fabry Disease (1)
Mallinckrodt (3) · Merck Sharp & Dohme LLC (3) · Biogen (2) · TG Therapeutics, Inc. (2) · University of California, Los Angeles (2) · Albert Einstein College of Medicine (1) · Amgen (1) · Amicus Therapeutics (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Aultman Health Foundation (1) · Basilea Pharmaceutica (1) · Dr. Marie Eve Sophie Bussiere-Cote (1) · GlaxoSmithKline (1) · Gynecologic Oncology Associates (1)
United States (24) · France (8) · Germany (8) · Spain (8) · Italy (6) · Ukraine (6) · Canada (5) · China (5) · Japan (5) · South Korea (5) · United Kingdom (5) · Australia (4) · Belgium (4) · Brazil (4) · Chile (4)
Andrew S Little, MD (1) · Ashley Waddington, MD, MPA (1) · Candy Estevez, M.Sc (1) · Daniel Kantor, MD (1) · David Han, MD (1) · Eddie M Irizarry, MD (1) · Eduardo Schiffer, MD (1) · John P Micha, MD (1) · Joshua H Cho, MD, PhD (1) · Laura K Randolph, DO, MS (1) · Leah R Battista, MD (1)
PMID 36001711, PMID 39512280, PMID 41787239, PMID 42292352, PMID 21353105, PMID 23852695, PMID 25199059, PMID 26049148, PMID 26554876, PMID 27087007, PMID 28298041, PMID 28687231, PMID 29258789, PMID 29398640, PMID 29949045, PMID 30936738, PMID 30954640, PMID 30975187, PMID 31047111, PMID 31251094, PMID 31262378, PMID 31447130, PMID 32450626, PMID 32515118, PMID 32557715, PMID 33300372, PMID 33475231, PMID 34098955, PMID 34158028, PMID 35119481, PMID 35421228, PMID 37131185, PMID 38648580, PMID 39798578, PMID 40202593, PMID 42573995
2017 (2), 2023 (2), 2009 (1), 2019 (1), 2025 (1), R21MH113915 (1)